Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study

Arthritis Rheumatol. 2014 Nov;66(11):3241-3. doi: 10.1002/art.38777.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Blood Sedimentation
  • C-Reactive Protein / metabolism
  • Child
  • Colchicine / therapeutic use*
  • Dose-Response Relationship, Drug
  • Drug Resistance*
  • Familial Mediterranean Fever / drug therapy*
  • Familial Mediterranean Fever / metabolism
  • Female
  • Humans
  • Interleukin-1beta / immunology*
  • Male
  • Outcome Assessment, Health Care
  • Pilot Projects
  • Time Factors
  • Treatment Failure
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Interleukin-1beta
  • canakinumab
  • C-Reactive Protein
  • Colchicine